Synergistic growth inhibition by afatinib and trametinib in preclinical oral squamous cell carcinoma models / Yee Pei San

Oral squamous cell carcinoma (OSCC) remains a challenging disease to manage due to limited efficacious treatments, hence finding more effective treatment approaches remains a priority. Given that the aberrant activation of epidermal growth factor receptor family receptors (ERBB) is a common event...